Voyager Therapeutics (Voyager Therapeutics) Interest Coverage

: N/A (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Voyager Therapeutics's Operating Income for the three months ended in Dec. 2023 was $54.1 Mil. Voyager Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.0 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Voyager Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Voyager Therapeutics's Interest Coverage or its related term are showing as below:

VYGR's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Voyager Therapeutics Interest Coverage Historical Data

The historical data trend for Voyager Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

N/A

Voyager Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage																N/A	N/A	N/A	N/A	N/A

Competitive Comparison

For the Biotechnology subindustry, Voyager Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Interest Coverage falls into.

Voyager Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Voyager Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Voyager Therapeutics's Interest Expense was $0.0 Mil. Its Operating Income was $122.0 Mil. And its Long-Term Debt & Capital Lease Obligation was $17.1 Mil.

GuruFocus does not calculate Voyager Therapeutics's interest coverage with the available data.

Voyager Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Voyager Therapeutics's Interest Expense was $0.0 Mil. Its Operating Income was $54.1 Mil. And its Long-Term Debt & Capital Lease Obligation was $17.1 Mil.

GuruFocus does not calculate Voyager Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

Voyager Therapeutics (NAS:VYGR) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Voyager Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (Voyager Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (NAS:VYGR) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

VT6:Germany VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Executives

Todd Alfred Carter	officer: Chief Scientific Officer	C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
Robin Swartz	officer: Chief Operating Officer	C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Peter P. Pfreundschuh	officer: Chief Financial Officer	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandell Jacquelyn Fahey	officer: Chief Legal Officer	C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
George A Scangos	director	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Alfred Sandrock	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Robert W. Hesslein	officer: Senior VP & General Counsel	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Jude Onyia	director	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Neurocrine Biosciences Inc	10 percent owner	12780 EL CAMINO REAL, SAN DIEGO CA 92130
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Grace Colon	director	C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Glenn Pierce	director
Michael J Higgins	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140